Email updates

Keep up to date with the latest news and content from BMC Research Notes and BioMed Central.

Open Access Case Report

Cabergoline therapy for Macroprolactinoma during pregnancy: A case report

Hira Shahzad1*, Aisha Sheikh2 and Lumaan Sheikh3

Author Affiliations

1 Medical College, Aga Khan University Hospital, Karachi, Pakistan

2 Department of Medicine, Aga Khan University Hospital, Karachi, Pakistan

3 Section of Feto-maternal Medicine and Neonatal Health Division of Woman and Child Health, Aga Khan University Hospital, Karachi, Pakistan

For all author emails, please log on.

BMC Research Notes 2012, 5:606  doi:10.1186/1756-0500-5-606

Published: 31 October 2012



We assessed the safety of Cabergoline therapy during pregnancy in a lady with hyperprolactinemia intolerant to Bromocriptine.

Case presentation

We report the case of a 31 year old lady who presented to us with uncontrolled hyperprolactinemia. A pituitary Macroadenoma was demonstrated by MRI. Due to intolerance to Bromocriptine, Cabergoline was started. The patient improved and subsequently conceived. MRI in the second trimester demonstrated further reduction in the tumor size. It was decided to continue Cabergoline throughout pregnancy to ensure further reduction in tumor size until delivery and to hold Cabergoline during postpartum period to allow for an adequate interval of breastfeeding. At 37 weeks of gestation, the patient delivered a healthy baby.


We were able to safely treat macroprolactinemia in our patient during pregnancy with cabergoline. This case report contributes to the relatively meager data available which advocates the safety of cabergoline therapy in pregnant hyperprolactinemic patients.